Skip to main content
SpringerLink
Log in

Development and Validation of RP-HPLC Method for the Simultaneous Estimation of Eight Related Substances in Milrinone API

  • Original
  • Published:
Chromatographia Aims and scope Submit manuscript

Abstract

A simple, quick, and economical reverse-phase high-performance liquid chromatography (RP-HPLC) method for the quantitative determination of related substance in milrinone API was developed and validated. The method has shown adequate separation of milrinone and eight kinds of related substance. Chromatographic separation was achieved on an Agilent ZORBAX Rx-C8 (250 × 4.6 mm, 5 µm) column at wavelength of 220 nm, using a mobile phase acetonitrile: phosphate buffer (85:15) in an isocratic elution mode at a flow rate of 1.0 mL min−1. The method was validated in terms of system suitability, specificity, linearity, range, accuracy, intermediate precision, and robustness. A linear relationship between peak area and concentration of milrinone and its related substances was observed in a level of 10–300% (determination coefficient, r2 ≥ 0.998), respectively. The method showed acceptable levels of precision (%RSD ≤ 2), accuracy (> 96% recovery), robustness (< 10% content difference), and stability (> 96% recovery) over varied environment and laboratory conditions. The validation results suggested that the developed method is sensitive enough and repeatable and could be used for qualitative and quantitative assessment of eight kinds of related substance in milrinone. As a significant part of drug development process, stress testing is also performed to identify the degradation products and validate the stability-indicating power of our analytical methods, in which milrinone is subjected to acidic, base, oxidation, thermal and photolytic stress environment. To sum up, the proposed method is suitable for purpose in quality-control laboratories for quantitative analysis of the drugs individually, as it is simple and rapid with good precision and accuracy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

Data availability

The data that support the findings of this study are available from the corresponding author, (Zhong Feng), upon reasonable request.

References

  1. Nunavath RS, Bhadram KC, Nagappan K (2023) Characterization, quantification and a multi-computational in silico toxicity assessment of impurity (feruloyl methane) in synthetic curcumin using RP-HPLC-UV technique. J Pharm Biomed Anal 235:115614

    Article  CAS  PubMed  Google Scholar 

  2. Yao K, Wang HF, Xie XD, Li JW, You RL, Li Y, Zhang H (2023) HPLC separation, synthesis, isolation and characterization of process related and degradation impurities in larotaxel including method development and validation. J Pharm Biomed Anal 233:115435

    Article  CAS  PubMed  Google Scholar 

  3. Huang YW, Lu H, Li Z, Zeng Y, Xu Q, Wu Y (2023) Development of HPLC-CAD method for simultaneous quantification of nine related substances in ursodeoxycholic acid and identification of two unknown impurities by HPLC-Q-TOF-MS. J Pharm Biomed Anal 229:115357

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Rao WB, Li LJ, Zhang CX, Zheng JF, Fan XM, Luan BL, Sun JX, Qiu MY, Wu SM, Li YH, Wang ZQ (2023) Development and validation of a stability-indicating RP-HPLC method for the determination of fifteen impurities in rivaroxaban. J Pharm Biomed Anal 228:115325

    Article  CAS  PubMed  Google Scholar 

  5. Del Rio-Pertuz G, Benjanuwattra J, Phinyo P, Leelaviwat N, Mekraksakit P, Nair N (2023) The mortality benefit of milrinone as a continuous outpatient intravenous inotrope therapy in advanced heart failure: a systemic review and meta-analysis. Int J Heart Failure 5:106–110

    Article  Google Scholar 

  6. Rodenas-Alesina E, Luis Scolari F, Wang VN, Brahmbhatt DH, Mihajlovic V, Fung NL, Otsuki M, Billia F, Overgaard CB, Luk A (2023) Improved mortality and haemodynamics with milrinone in cardiogenic shock due to acute decompensated heart failure. ESC Heart Failure 10:2577–2587

    Article  PubMed  PubMed Central  Google Scholar 

  7. Viéitez Flórez JM, Hernández Pérez FJ, Mitroi C, Lozano Jiménez S, Gómez Bueno M, Segovia Cubero J (2023) Usefulness of ambulatory milrinone perfusion in a cohort of advanced heart failure patients. Rev Esp Cardiol (English ed) 76:386–388

    Google Scholar 

  8. Gerhartz B, Damodharan S, Puccetti DM, Boriosi JP, Hokanson JS, Capitini CM (2023) Use of milrinone to support therapy-induced heart failure through hematopoietic stem cell transplantation in a pediatric patient with high-risk FLT3+ acute myeloid leukemia. Pediatr Blood Cancer 70:e30542

    Article  PubMed  Google Scholar 

  9. Hasegawa GR (1986) Milrinone, a new agent for the treatment of congestive heart failure. Clin Pharm 5:201–205

    CAS  PubMed  Google Scholar 

  10. Young RA, Ward A (1988) Milrinone. A preliminary review of its pharmacological properties and therapeutic use. Drugs 36:158–192

    Article  CAS  PubMed  Google Scholar 

  11. Tang X, Liu P, Li R, Jing Q, Lv J, Liu LY (2015) Milrinone for the treatment of acute heart failure after acute myocardial infarction: a systematic review and meta-analysis. Basic Clin Pharmacol Toxicol 117:186–194

    Article  CAS  PubMed  Google Scholar 

  12. Koster G, Hanneke JB, Wetterslev J, Gluud C, Keus F, van der Horst IC (2016) Milrinone for cardiac dysfunction in critically ill adult patients: a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis. Intensive Care Med 42:1322–1335

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Dempsey E, Rabe H (2019) The use of cardiotonic drugs in neonates. Clin Perinatol 46:273–290

    Article  PubMed  Google Scholar 

  14. Alousi AA, Canter JM, Montenaro MJ, Fort DJ, Ferrari RA (1983) Cardiotonic activity of milrinone, a new and potent cardiac bipyridine, on the normal and failing heart of experimental animals. J Cardiovasc Pharmacol 5:792–803

    Article  CAS  PubMed  Google Scholar 

  15. Maskin CS, Sinoway L, Chadwick B, Sonnenblick EH, Le Jemte TH (1983) Sustained hemodynamic and clinical effects of a new cardiotonic agent, WIN 47203, in patients with severe congestive heart failure. Circulation 67:1065–1070

    Article  CAS  PubMed  Google Scholar 

  16. United States Pharmacopoeia/National Formulary (2018) 41th edn. Pharmacopeial Convention, Rockville, Maryland, p 1475

  17. Nageswara RR, Nagaraju V (2003) An overview of the recent trends in development of HPLC methods for determination of impurities in drugs. J Pharm Biomed Anal 33:335–377

    Article  Google Scholar 

  18. ICH Q3A (R2) (2006) Impurities in new drug substances (2006). In: International Conference on Harmonisation. Available from https://database.ich.org/sites/default/files/Q3A%28R2%29%20Guideline.pdf

  19. Kątny M, Frankowski M (2017) Impurities in drug products and active pharmaceutical ingredients. Crit Rev Anal Chem 47:187–193

    Article  PubMed  Google Scholar 

  20. Chew YL, Khor MA, Lim YY (2021) Choices of chromatographic methods as stability indicating assays for pharmaceutical products: a review. Heliyon 7:e06553

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Patel R, Purohit S, Solanki R, Khunt D, Patel C, Patel R, Parikh S (2023) Development and validation of an analytical method for trace-level quantification of genotoxic nitrosamine impurities in losartan and hydrochlorothiazide fixed-dose combination tablets using ultra performance liquid chromatography triple quadrupole mass spectrometry. Rapid Commun Mass Spectrom 37:e9488

    Article  CAS  PubMed  Google Scholar 

  22. ICH Q2 (R1) (2005) Validation of analytical procedures: text and methodology. In: International Conference on Harmonisation. Available from https://database.ich.org/sites/default/files/Q2%28R1%29%20Guideline.pdf

  23. Görög S (2008) Drug safety, drug quality, drug analysis. J Pharm Biomed Anal 48:247–253

    Article  PubMed  Google Scholar 

  24. Jain D, Basniwal PK (2013) Forced degradation and impurity profiling: recent trends in analytical perspectives. J Pharm Biomed Anal 86:11–35

    Article  CAS  PubMed  Google Scholar 

  25. Singh S, Junwal M, Modhe G, Tiwari H, Kurmi M, Parashar N, Sidduri P (2013) Forced degradation studies to assess the stability of drugs and products. Trends Anal Chem 49:71–88

    Article  CAS  Google Scholar 

  26. Blessy M, Patel RD, Prajapati PN, Agrawal YK (2014) Development of forced degradation and stability indicating studies of drugs—a review. J Pharm Anal 4:159–165

    Article  CAS  PubMed  Google Scholar 

  27. Sengupta P, Chatterjee B, Tekade RK (2018) Current regulatory requirements and practical approaches for stability analysis of pharmaceutical products: a comprehensive review. Int J Pharm 543:328–344

    Article  CAS  PubMed  Google Scholar 

  28. Shelke M, Deshpande SS, Sharma S (2020) Quinquennial review of progress in degradation studies and impurity profiling: an instrumental perspective statistics. Crit Rev Anal Chem 50:226–253

    Article  CAS  PubMed  Google Scholar 

  29. Jahani M, Fazly Bazzaz BS, Akaberi M, Rajabi O, Hadizadeh F (2023) Recent progresses in analytical perspectives of degradation studies and impurity profiling in pharmaceutical developments: an updated review. Crit Rev Anal Chem 53:1094–1115

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors are thankful to the Ocean University of China and Shandong New Time Pharmaceutical Co. Ltd, for supporting this work.

Funding

The research was supported by the Key R&D Program of Shandong Province, China (2020CXGC010506).

Author information

Authors and Affiliations

  1. Department of Pharmacy, School of Pharmacy, Ocean University of China, Qingdao, 266100, China

    Yujiang Pang, Zhengzhao Li & Zhong Feng

  2. International Pharmaceutical R&D Center, Lunan Pharmaceutical Group Co. Ltd, Shandong New Time Pharmaceutical Co. Ltd, Linyi, 276000, China

    Xiaoyan Shi, Zengyu Pan, Kai Liu, Xianyong Zhu & Zhong Feng

Authors
  1. Yujiang Pang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xiaoyan Shi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zhengzhao Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Zengyu Pan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kai Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Xianyong Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Zhong Feng
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

YP, XS, ZL and ZP wrote the main manuscript. KL and XZ performed the data and formal analysis. All authors performed the validation and reviewed the manuscript.

Corresponding author

Correspondence to Zhong Feng.

Ethics declarations

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pang, Y., Shi, X., Li, Z. et al. Development and Validation of RP-HPLC Method for the Simultaneous Estimation of Eight Related Substances in Milrinone API. Chromatographia 87, 105–115 (2024). https://doi.org/10.1007/s10337-023-04307-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10337-023-04307-7

Keywords

Search

Navigation